Cardiac Resynchronization Therapy Devices (CRT)

September 9, 2014 — Use of a quadripolar left ventricular (LV) lead instead of a bipolar option during cardiac resynchronization therapy (CRT) can decrease complications at six months, according to preliminary hot line results presented at the 201...

August 28, 2014 — Medtronic Inc. announced the U.S. Food and Drug Administration (FDA) approval of its newest cardiac resynchronization therapy-pacemaker, Viva CRT-P, for indicated patients with heart failure or atrioventricular (AV) block.

August 11, 2014 — Medtronic announced it has received U.S. Food and Drug Administration (FDA) approval for the Attain Performa model 4298 quadripolar lead, and the Viva Quad XT and Viva Quad S cardiac resynchronization therapy defibrillators (CRT-...

The U.S. Food and Drug Administration (FDA) approved an application from Medtronic for revised labeling for two cardiac resynchronization pacemakers (CRT-P) and eight cardiac resynchronization defibrillators (CRT-D), expanding the indication for u...

Cardiac Resynchonization Therapy (CRT), Implantable cardioverster defibrillators
Medtronic announced new results from the PainFree SST and Shock-Less clinical studies published in the journal HeartRhythm.
Medtronic AdaptResponse Global Clinical Trial Cardiac Resynchronization Therapy
Medtronic Inc. announced the first implants in a clinical trial that will compare patient and healthcare system outcomes — including patient...
September 9, 2014 — Use of a quadripolar left ventricular (LV) lead instead of a bipolar option during cardiac resynchronization therapy (CRT) can decrease...
August 28, 2014 — Medtronic Inc. announced the U.S. Food and Drug Administration (FDA) approval of its newest cardiac resynchronization therapy-pacemaker, Viva...
Medtronic Viva Quad XT CRT-D Adaptiv CRT
Medtronic received U.S. Food and Drug Administration (FDA) approval for the Attain Performa model 4298 quadripolar lead, and the Viva Quad
Medtronic offers an expanded indication for biventricular (BiV) pacing with Medtronic cardiac resynchronization therapy-pacemakers and -...
Biotronik’s Ilesto family of implantable cardioverter-defibrillator/cardiac resynchronization therapy defibrillators (ICD/CRT-D...
Biotronik announced the U.S. Food and Drug Administration (FDA) granted approval for its Ilesto 7 implantable cardioverter-...

Articles

September 9, 2014 — Use of a quadripolar left ventricular (LV) lead instead of a bipolar option during cardiac resynchronization therapy (CRT) can decrease...
May 14, 2014 — Data presented during Heart Rhythm 2014 found the use of quadripolar leads reduced the number of hospitalizations by 53 percent when...
Medtronic announced the U.S. Food and Drug Administration (FDA) approved an expanded indication for biventricular (BiV) pacing with Medtronic cardiac...
ICD, MADIT-CRT trial, long-term followup, ACC.14
Patients in mild heart failure who receive a cardiac resynchronization therapy defibrillator (CRT-D) device may live longer than those implanted with...

Video Center

It’s been no secret that the American healthcare system needed to change to survive economically...
2 weeks 3 days ago
The silence is deafening. And since radiology associations, physician groups and vendors have yet...
4 weeks 3 days ago
The America College of Cardiology has released its list of key late-breaking clinical trials at the...
5 weeks 4 days ago
The webinar "State of the Art in MRI Pediatric Brain Perfusion Imaging" educates participants about the state of the art clinical and emerging translational...
This webinar discusses why contemporary adult cardiac interventions require significant ionizing radiation with potential health risks to both the patient and...
This webinar explained the benefits of better access, productivity and revenue cycle efficiency in a modern cardiovascular information system (CVIS...